ARTICLE | Company News
Ziarco, Novartis deal
December 30, 2016 9:57 PM UTC
Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389, an oral histamine H4 receptor (HRH4; H4) antagonist. Ziarco previously said ZPL-389 missed the primary ...
BCIQ Target Profiles